应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
DRUG Bright Minds Biosciences Inc
已收盘 04-24 16:00:00 EDT
1.09
-0.03
-2.68%
最高
1.20
最低
1.09
成交量
3,222
今开
1.13
昨收
1.12
日振幅
9.52%
总市值
486.56万
流通市值
346.98万
总股本
446.38万
成交额
3,608
换手率
0.10%
流通股本
318.33万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
HUIADGENE ANNOUNCES RARE PEDIATRIC DRUG DESIGNATION GRANTED TO HG302, A NOVEL CRISPR DNA-EDITING THERAPY, FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
StreetInsider · 2023-12-19
HUIADGENE ANNOUNCES RARE PEDIATRIC DRUG DESIGNATION GRANTED TO HG302, A NOVEL CRISPR DNA-EDITING THERAPY, FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
加载更多
公司概况
公司名称：
Bright Minds Biosciences Inc
所属市场：
NASDAQ
上市日期：
--
主营业务：
Bright Minds Biosciences Inc.于2019年5月31日根据不列颠哥伦比亚省商业公司法注册成立。该公司是一家生物技术公司，致力于开发治疗方法，以改善患有严重疾病患者的生活。该公司正在创造新的化学实体作为靶向治疗剂，用于治疗以血清素(5-HT)受体(5-HT2A、5-HT2C或5-HT2A/C)驱动机制为基础病理的疾病。
发行价格：
--
{"stockData":{"symbol":"DRUG","market":"US","secType":"STK","nameCN":"Bright Minds Biosciences Inc","latestPrice":1.09,"timestamp":1713988800000,"preClose":1.12,"halted":0,"volume":3222,"delay":0,"floatShares":3183337,"shares":4463837,"eps":-1.347133,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.03,"latestTime":"04-24 16:00:00 EDT","open":1.13,"high":1.1966,"low":1.09,"amount":3608.354531,"amplitude":0.095179,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.347133,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714032000000},"adr":0,"adjPreClose":1.12,"preHourTrading":{"tag":"盘前","latestPrice":1.13,"preClose":1.12,"latestTime":"08:00 EDT","volume":53,"amount":59.88999999999999,"timestamp":1713960000610},"volumeRatio":0.30739},"requestUrl":"/m/hq/s/DRUG","defaultTab":"news","newsList":[{"id":"2392197084","title":"HUIADGENE ANNOUNCES RARE PEDIATRIC DRUG DESIGNATION GRANTED TO HG302, A NOVEL CRISPR DNA-EDITING THERAPY, FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY","url":"https://stock-news.laohu8.com/highlight/detail?id=2392197084","media":"StreetInsider","top":-1,"share":"https://www.laohu8.com/m/news/2392197084?lang=zh_cn&edition=full","pubTime":"2023-12-19 20:00","pubTimestamp":1702987200,"startTime":"0","endTime":"0","summary":"HG302 effectively generates stable genome editing with minimal off-target effects in-vitro and in-vivoA single intravenous injection of HG302 restores functional dystrophin protein expression HG302 demonstrates therapeutic effects by improving muscle functions in humanized DMD miceSHANGHAI and CLINTON, N.J., Dec. 19, 2023 /PRNewswire/ -- HuidaGene Therapeutics today announced the U.S. FDA granted Rare Pediatric Drug Designation to HG302, a novel CRISPR-Cas12 DNA-editing therapy, to treat Duchenne muscular dystrophy , affecting 1 in ~5,000 newborn boys.HuidaGene Announces RPDD Granted to HG302, A Novel CRISPR DNA-editing Therapy, for the Treatment of DMDUnlike the in-vivo use of Cas9 system with limited genome-editing efficiency, high occurrence of off-targeting modifications, viral delivery packaging limitations, and complicated CRISPR-Cas9 patent dispute, HuidaGene identified novel Cas12i proteins using AI and deep machine-learning of DNA sequencing through the proprietary HG-PRECIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22543035","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.brightmindsbio.com","stockEarnings":[{"period":"1week","weight":-0.0175},{"period":"1month","weight":-0.0894},{"period":"3month","weight":-0.4167},{"period":"6month","weight":-0.2168},{"period":"1year","weight":-0.6043},{"period":"ytd","weight":-0.2168}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":-0.0299},{"period":"3month","weight":0.0417},{"period":"6month","weight":0.2257},{"period":"1year","weight":0.2254},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bright Minds Biosciences Inc.于2019年5月31日根据不列颠哥伦比亚省商业公司法注册成立。该公司是一家生物技术公司，致力于开发治疗方法，以改善患有严重疾病患者的生活。该公司正在创造新的化学实体作为靶向治疗剂，用于治疗以血清素(5-HT)受体(5-HT2A、5-HT2C或5-HT2A/C)驱动机制为基础病理的疾病。","exchange":"NASDAQ","name":"Bright Minds Biosciences Inc","nameEN":"Bright Minds Biosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bright Minds Biosciences Inc(DRUG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bright Minds Biosciences Inc(DRUG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bright Minds Biosciences Inc,DRUG,Bright Minds Biosciences Inc股票,Bright Minds Biosciences Inc股票老虎,Bright Minds Biosciences Inc股票老虎国际,Bright Minds Biosciences Inc行情,Bright Minds Biosciences Inc股票行情,Bright Minds Biosciences Inc股价,Bright Minds Biosciences Inc股市,Bright Minds Biosciences Inc股票价格,Bright Minds Biosciences Inc股票交易,Bright Minds Biosciences Inc股票购买,Bright Minds Biosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bright Minds Biosciences Inc(DRUG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bright Minds Biosciences Inc(DRUG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}